Encysive Pharmaceuticals — BIO CEO & Investor Conference 2007
24 slides from Encysive Pharmaceuticals's conference presentation, Feb 13, 2007

Slide 1: BIO CEO & Investor Conference February 12-14, 2007
BIO CEO & Investor Conference February 12-14, 2007

Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are subject to certain risks, trends an

Slide 3: Overview
Overview Encysive is engaged in the development and commercialization of novel, synthetic, small molecule compounds in the area of vascular biology Company headquarters in Houston; European operations (Encysive UK Ltd) based outside London First product (Argatroban) approved and marketed by GlaxoSmi

Slide 4: Investment Highlights
Investment Highlights In August 2006 THELIN(r) (sitaxentan sodium) 100 mg tablets approved for treatment of PAH in all 27 countries of European Union Launched in the UK in Nov. Launched in Germany in Dec.

Slide 5: Investment Highlights
Investment Highlights 3 additional regulatory reviews pending for THELIN(tm) US FDA "approvable letter" Australia (positive opinion granted) Canada Commercial organization in place in both United States and Europe Attractive product opportunity ENCY owns 100% of worldwide THELIN revenues Efficient m

Slide 6: Pulmonary Arterial Hypertension (PAH)
Pulmonary Arterial Hypertension (PAH) Rare, life-threatening condition causing high blood pressure in the lungs due to narrowing and stiffening of pulmonary arteries Symptoms include shortness of breath, fatigue, dizzy spells, fainting, chest pain, and swelling of ankles and legs PAH may develop wit

Slide 7: PAH - A Growing Market Opportunity
PAH - A Growing Market Opportunity... Estimated 100,000 - 200,000 patients in North America and Europe Market still growing rapidly Physician awareness continues to grow Estimated $700MM in ETRA product sales in 2006 with double digit growth New entrant can fuel growth Rate of diagnosis continues to

Slide 8: Diagnosed PAH Patients Projected to Double by 2009
Diagnosed PAH Patients Projected to Double by 2009... Source: Encysive Internal Market Model, 2005

Slide 9: Basis for Regulatory Submissions
Basis for Regulatory Submissions Two successful pivotal trials completed (STRIDE-1, STRIDE-2) More than 1,000 PAH patients treated with THELIN(tm) in clinical studies

Slide 10: STRIDE-1: Efficacy
STRIDE-1: Efficacy At 12 weeks, THELIN(tm) 100 mg (vs. placebo) improved: 6MW distance (placebo-corrected 35 m, p < 0.01) WHO FC (29% improved, p < 0.02) Hemodynamics PVR decreased 221 dyn/sec/cm-5 (p < 0.001) CI increased 0.3 L/min/m2 (p < 0.02) Barst RJ, et al. Am J Respir Crit Care Med. 2004;169:

Slide 11: STRIDE-2: Efficacy
STRIDE-2: Efficacy Treatment with THELIN(tm) 100 mg (vs. placebo) at 18 weeks: Increased 6MW distance: treatment effect 31.4 m (p= 0.03) Improved WHO functional class: 98% improved or unchanged (p= 0.04) Barst RJ, et al. J Am Coll Cardiol. 2006;47:2049-2056

Slide 12: THELIN Safety and Tolerability
THELIN(tm) Safety and Tolerability Favorable liver function test (LFT) elevations* STRIDE-1 (12 Weeks) 0% for THELIN 100 mg 3% for Placebo STRIDE-2 (18 Weeks) 3% for THELIN 100 mg 6% for Placebo 11% for Tracleer(r) Class effect seen with THELIN, Tracleer and ambrisentan * Single elevation greater th

Slide 13: THELIN Safety and Tolerability
THELIN(tm) Safety and Tolerability Adverse events typical for vasodilators E.g.: Headache, nasal congestion, nausea, edema Well-characterized interaction with warfarin Handled by dose adjustment Warfarin requires close monitoring irrespective of treatment selection Monthly liver and pregnancy* testi

Slide 14: THELIN Approved in the EU
THELIN(r) Approved in the EU Approved in August 2006 for marketing in all 27 EU countries THELIN 100 mg indicated for the treatment of patients with PAH classified as World Health Organization functional class III, to improve exercise capacity. Efficacy has been shown in primary (idiopathic) pulmona

Slide 15: THELIN in EU: A 2nd Generation ETRA with Competitive Advantages
THELIN(r) in EU: A 2nd Generation ETRA with Competitive Advantages Once-daily oral tablet Lower rate of liver function test elevations Efficacy demonstrated in PAH associated with CTD No clinically meaningful interaction with sildenafil Only highly selective ETRA for PAH Only ETRA with comparator da

Slide 16: EU Operations
EU Operations Established EU operations headed by Thierry Plouvier, M.D., headquartered in London Approximately 35 sales reps. planned for Europe UK & German sales organizations in place Additional key countries targeted for 2007 launch Spain France Italy Netherlands

Slide 17: Ready to Launch in the US
Ready to Launch in the US Sales representatives trained, ready-to-go Average 11 years pharmaceutical sales experience Comments received from FDA on ENCY's plans for its risk map Managed care team in place Top 50 payers targeted Company continues to believe that retaining the U.S. sales force is the

Slide 18: US Regulatory Status
US Regulatory Status Second FDA "approvable letter" for THELIN(tm) received on July 24 Complete Response accepted Dec. 28 New PDUFA action date June 15, 2007 We remain hopeful that approval can be achieved without additional clinical work

Slide 19: Pipeline Chart
Pipeline Chart PROPRIETARY PRODUCTS Thelin(tm) Oral Thelin(tm) Oral- US PC1 Oral PC2 Oral PC3 Intravenous PAH Undisclosed ILD Thelin(tm) Oral Undisclosed Undisclosed TBC3711 Oral Thelin(tm) Intravenous TBC3711 Intravenous Undisclosed Undisclosed Undisclosed Resistant HTN Undisclosed PARTNERED PRODUC

Slide 20: Senior Management Team with Significant Global Pharmaceutical Experience
Senior Management Team with Significant Global Pharmaceutical Experience... Bruce Given, M.D. President and CEO Formerly President, International of Ortho - -Clinical Diagnostics a Johnson & Johnson Company George Cole COO Formerly President of Altana Pharma U.S. Richard Dixon, Ph.D. CSO Formerly Di

Slide 21: Financial Highlights
Financial Highlights Cash & investments at September 30, 2006 $49.9M Azimuth Opportunity Ltd. Equity Line Up to $75.0M* Note offering backed by Argatroban royalty $55.0M** *$18M drawn down to date. Currently, can only draw down another approx. $30M. **$10M pending UK tax relief.

Slide 22: Summary
Summary In US: 1 product approved, and 1 "approvable" In EU: THELIN approved -- launched in UK & Germany 3 active regulatory filings Ready for US commercial launch Additional indications for THELIN(tm) in clinical development

Slide 23: Forward-Looking Statements
Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are subject to certain risks, trends an

Slide 24: BIO CEO & Investor Conference February 12-14, 2007
BIO CEO & Investor Conference February 12-14, 2007
Source: SEC EDGAR · 8-K filed Feb 13, 2007
More decks from Encysive Pharmaceuticals Inc
26th Annual JPMorgan Healthcare Conference 200825 slides · Jan 8, 2008
2007 UBS Global Life Sciences Conference21 slides · Sep 24, 2007
Cowen and Company 27th Annual Health Care Conference 200724 slides · Mar 13, 2007
Rodman & Renshaw Healthcare Conference 200625 slides · Nov 6, 2006
ThinkEquity Partners 4th Annual Growth Conference 200625 slides · Sep 11, 2006
JPMorgan Healthcare Conference 200627 slides · Jan 9, 2006